A synthetic decapeptide analog of GnRH that stimulates the pituitary gland to release FSH and LH, aiding in reproductive hormone regulation and fertility treatments.
A study of nearly 2,000 frozen‑embryo transfers found that giving overweight or obese women a depot GnRH‑agonist (gonadorelin) before the usual hormone‑replacement prep raised their chances of a live birth from about 49% to 56%, especially if they also have abnormal blood lipids.
Slack. Daniel J DJ; Krishnamurthy. Nithya N; Garrity. Meghan M; Chen. Derek D; Kyweluk. Moira M; Tra...
The study looked at 9,916 trans women on estrogen and found that testosterone levels drop when estradiol goes up, but the two hormones don’t move together in a simple way. Things like having the testicles removed, being older, or taking spironolactone change testosterone levels but not estradiol. Testosterone also tracks with LH, while estradiol does not. So, for people doing gender‑affirming hormone therapy, checking testosterone (and LH if you don’t have testicles) is more useful than just checking estradiol.
Yi. Xi X; Tian. Dongmei D; Li. Hengli H; Zhou. Guanhua G
A study of 1,454 frozen embryo transfers found that using a GnRH agonist (gonadorelin) before the usual hormone replacement therapy makes the uterine lining a bit thicker and improves the chance of a live birth when only one embryo is transferred. The benefit was strongest for women with endometriosis, while women with PCOS or tubal issues did just as well (and saved time and money) with the standard hormone protocol.
Schnell. Vicki L VL; Bredeson. Liesl K LK; Brown. Eric E; Chan. Anna A; Thomas. James J; Simon. Jame...
A 5‑year study showed that taking the GnRH‑blocking drug elagolix together with low‑dose estrogen/progestin (add‑back) for up to 48 months only caused a tiny (<2%) drop in bone density, and most of the loss healed after stopping the drug. Side effects were mostly mild, and bone‑related problems were uncommon.
Imbroane. Marisa M; Bussies. Parker P; Schachter. Cara C; Frankel. Lexi L; Bosch. Allison A; Santaro...
The review updates the drug options for treating endometriosis, a painful, inflammatory condition that affects about 10% of people who can get pregnant. It confirms that common first‑line medicines like NSAIDs, birth‑control pills, and progestins still work best, while stronger hormonal blockers (GnRH agonists/antagonists) and aromatase inhibitors are used when symptoms persist. New strategies such as adding low‑dose estrogen (add‑back therapy) to reduce side effects, and experimental non‑hormonal approaches, are also discussed.
Wells. K V KV; Goodson. M L ML; Lim. K E KE; Robling. A G AG; Genetos. D C DC
In mice, drugs that lower testosterone (like GnRH agonists) hurt bone, but giving estrogen fixes the bone loss better than giving testosterone. Estrogen alone can also boost bone strength while keeping testosterone low, but it also ramps up bone‑cell activity that might help prostate cancer spread to bone.
Degarelix, a GnRH‑antagonist, causes faster and more lasting testosterone drop than traditional GnRH‑agonists, cuts down heart‑related and muscle‑joint side effects, but it gives many more injection‑site reactions and overall mild side effects.
Relugolix is an oral drug that blocks the hormone signals that tell the testes to make testosterone. In advanced prostate cancer, it lowers testosterone faster and more reliably than the older injectable drugs, and it cuts the risk of serious heart problems by about half. It also lets testosterone bounce back more quickly after treatment stops, which could matter for men who care about hormone balance and heart health.
In boys treated with a long‑acting GnRH‑analogue (leuprolide) for early puberty, overall body‑mass‑index (BMI) stayed about the same during the first two years, then dropped after treatment ended. Kids who started at a normal weight tended to gain weight in the first year, while those who were already overweight or obese mostly kept their weight or even lost it. By the time they reached adult height, normal‑weight boys were back to their original BMI, overweight boys stayed the same, and obese boys ended up lighter.
Eslami. Hadi H; Nemati. Arezoo A; Jamshidi. Mahdieh M; Ghaffarian-Bahraman. Ali A; Askari. Sahar Gha...
This review shows that many everyday cosmetics like lipstick, deodorant, and nail polish can expose pregnant women and babies to harmful chemicals called phthalates, which can mess up hormones, liver, kidney, and even affect birth outcomes. It points out specific biomarkers you can track and suggests swapping phthalates for safer ingredients like citrates to cut down exposure.
Wilkinson. Jane Frances JF; Williams. Paula L PL; Green. Jan Catherine JC; Modi. Simon S; Briggs. Pa...
A 47‑year‑old woman with a known long QT heart condition was given GnRH drugs to force menopause before a hysterectomy. The hormone change triggered dangerous heart rhythm problems, including ventricular fibrillation and Torsades de Pointes, leading to cardiac arrests. The paper explains how female hormones affect the QT interval and warns that messing with them can be risky for people with heart rhythm issues.
van Eeghen. Sarah S; Pyle. Laura L; Narongkiatikhun. Phoom P; Choi. Ye Ji YJ; Vosters. Taryn T; van...
A three‑month study found that women‑type hormone therapy (high estradiol plus a GnRH analogue to keep testosterone low) boosted insulin sensitivity by about 20%, while testosterone‑only therapy didn’t change it. Changes in blood proteins tied to inflammation, iron handling, and oxidative stress were linked to the insulin improvements.
Menopause isn’t just about the ovaries stopping; it’s a whole‑body shift that changes brain signals, inflammation, and cell power plants. When estrogen drops, the brain’s GnRH pulses get messed up because of changes in kisspeptin, neurokinin B, and GABA, leading to hot flashes and irregular cycles. New drugs that block neurokinin receptors or selectively target estrogen‑beta receptors might help more than traditional hormone pills.
Researchers created a tiny needle patch that dissolves quickly and drops goserelin‑containing microspheres into the skin, releasing the drug steadily for about a month. It works as well as the usual painful muscle shots and appears safe, offering a less invasive way to give this hormone‑blocking peptide.
Yuan. Fang F; Zhang. Ping P; Liu. Ming M; Li. Yuan Y; Xu. Bin B; Li. Xin X
A 37‑year‑old woman in a phase‑I trial got serious liver damage after taking the GnRH‑like peptide alarelin acetate (150 µg daily). The injury cleared after stopping the drug and using liver‑support supplements. Genetic testing showed she carried a NUDT15 loss‑of‑function variant and certain HLA alleles that might make her more prone to this liver toxicity.
Gonçalves. Maria M; Cunha. Mariana M; Teixeira da Silva. José J; Silva. Joaquina J; Viana....
In women who produce a lot of eggs during IVF, using a GnRH‑agonist (like gonadorelin) to trigger egg release works just as well as the traditional hCG trigger when a small dose of hCG is given later to support the lining. Freezing all embryos and transferring them later eliminates the risk of severe ovarian hyperstimulation syndrome (OHSS) without hurting pregnancy chances.
In a Danish study of transgender teens, many were already overweight or had bad cholesterol before any hormone treatment. Using a GnRH‑blocking peptide (like gonadorelin) alone slightly lowered weight but didn’t consistently change BMI or blood fats. Adding sex hormones later caused boys to lose some good cholesterol (HDL) and gain triglycerides, while girls saw a rise in HDL. Overall, the peptide itself isn’t a major driver of weight or lipid problems, but the added sex steroids do shift blood‑fat profiles.
A review of studies shows that using high‑intensity focused ultrasound (HIFU) together with hormone drugs like GnRH agonists (e.g., gonadorelin) can shrink adenomyosis lesions better, lower pain, and may improve chances of getting pregnant compared to using either treatment alone. However, the data are still limited and long‑term fertility results are unclear.
In a rat model of PCOS, the diabetes drug liraglutide (a GLP‑1 receptor agonist) lowered testosterone and luteinizing hormone, helped restore normal estrous cycles, and fixed ovarian problems. The researchers discovered that the drug works by boosting a brain protein called RASA1, which then dampens GnRH (the hormone that triggers LH/FSH release) through the Ras/AKT signaling pathway. Tweaking RASA1 or AKT in the brain mimicked the drug’s effects, showing this pathway is a key control point for the reproductive hormone imbalance seen in PCOS.
Su. Weijue W; Zhang. Lei L; Cheng. Jing J; Fu. Yanghua Y; Zhao. Junzhao J; Chen. Haoying H
In women with PCOS, being overweight or obese makes IVF less successful. The study found that obese patients retrieved fewer eggs and had lower live‑birth rates, especially when using frozen embryos. Weight loss before starting an IVF cycle could improve the chances of having a baby.